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In addition to neuritic changes and amyloid deposits, neuronal and glial cell apoptosis is 
an important pathological feature of  Alzheimer’s disease (AD).  Several factors have 
been postulated as causes or triggers of  cellular apoptotic change.  This study focused 
on a quantifiable relationship between phosphorylation sites of  tau protein in the 
neurofibrillary tangles (NFT) and neuronal apoptosis.  Five monoclonal anti-tau 
antibodies (AT180, AT8, HT7, Tau2 and Tau5) for NFT labeling and TdT-mediated UTP 
nick-end labeling (TUNEL) for localizing apoptotic change were employed.  
TUNEL-stained neuronal nuclei showed significantly high density in the entorhinal cortex, 
cornu ammonis (CA) and the parietal cortex.  In all regions, density of  TUNEL-stained 
neuronal nuclei showed significantly direct correlation with that of  AT8-, AT180- and 
Tau2-positive neurons.  Correlation of  TUNEL-stained neuronal nuclei with tau-positive 
neurons differed depending on the cerebral regions.  Density of  TUNEL-stained 
neuronal nuclei showed inverse correlation with that of  both AT8-positive and 
Gallyas-stained NFT in the CA and showed significantly direct correlation with AT8- and 
HT7-positive neurons in the frontal cortex.  Density of  tau-positive and Gallyas-stained 
NFT was higher than that of  TUNEL-stained nuclei.  We conclude that phosphorylation 
sites of  tau, 159-163 and 202-205, are probably associated with neuronal apoptosis and 
apoptotic change follows abnormal phosphorylation of  tau.   
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Introduction 
Apoptosis, a programmed cell death by intrinsic mechanism to regulate cell population, 
has been shown to occur extensively in brains from patients with Alzheimer’s disease 
(AD).  In addition to neurofibrillary tangles (NFT) and beta amyloid protein (BAP) 
deposits, abundant apoptotic neuronal and glial cells are another pathological hallmark of  
AD [1-18].  Abnormal phosphorylation of  the tau protein that leads to NFT formation, 
BAP deposits, high concentration of  amyloid precursor protein (APP), caspase-3, the 
presenilin 1 and 2 gene and nitric oxide are considered to be important triggers of  
neuronal and glial apoptosis [1-25].  Since NFT are present in the neuronal cytoplasm, 
NFT and neuronal apoptosis have been considered to be intimately associated with each 
other.  To the best of  our knowledge, 13 studies, ten in vivo [1, 3, 5, 7, 8-10, 13, 16, 18] 
and three in vitro [15, 18, 22], have addressed the relationship between NFT formation 
and neuronal apoptosis.  However, it is still unclear whether neuronal apoptosis is a 
result or cause of  abnormal phosphorylation of  tau. 
Tau immunohistochemistry has differentiated pretangle neurons, known as stage 
0 tangles [26-27], from argyrophilic NFT, and phosphorylation sites of  the amino acid 
sequence of  tau molecules have been analyzed in AD brains [28-29].  The pretangle 
neurons are believed to occur in the early stage and may disappear in the late stage of  AD 
with some of  them remaining unchanged.  A recent study has demonstrated that 
neurons with normal nuclear morphology, known as type 1 [1], positive for TdT-mediated 
UTP nick end-labeling (TUNEL) contained abundant hyperphosphorylated tau, but type 
2 TUNEL-positive nuclei, loss of  nucleolus [1], were shown not to be associated with 
either NFT or senile plaques [18]. 
 The tau protein consists of  441 amino acid long sequences.  AD-associated 
abnormal phosphorylation of  the tau protein occurs at serine 202 and is predominant in 
the neurites [30].  The phosphorylation site can be detected with AT8 because the 
phosphorylation site of  the amino acid sequence of  202-205 is recognized by AT8 [31-32].  
Many anti-tau antibodies have been shown to recognize different sites of  abnormal 
phosphorylation in AD [28-29, 33-34].  Other phosphorylation sites of  tau protein are 
231 detectable by AT180, 95-108 detectable by Tau2, and 159-163 detectable by HT7.  
The sites of  tau amino acid sequences recognized by Tau5 are not exactly known, but it 
has been speculated that they are located in the central zone of  the tau molecule. 
 For the study presented here, we performed an immunohistochemical and 
quantitative study to determine any quantifiable relationship between the phosphorylation 
site of  the tau protein and TUNEL-stained nuclei in AD brains. 
 
Materials and methods 
Seven brains from patients with AD and seven controls [25], all of  whom met the 
diagnostic pathological criteria for AD [35-36], were enrolled in this study.  The 
post-mortem delay ranged from 3.0 to 8.4 hours (average 3.7 hours) [25].  The brains 
removed at autopsy were fixed with 10% formalin, and brain slices were cut coronally and 
embedded in paraffin wax.  Representative hemispheric sections that contained the 
frontal, temporal, parietal and occipital lobes, hippocampus and basal ganglia were sliced 
to a thickness of  7µm.  Pathologic examination was performed with hematoxylin and 
eosin (H-E), luxol-fast blue (LFB) and cresyl violet, Holzer and Bodian stains.  
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Immunohistochemistry employed an avidin-biotin peroxidase complex (ABC) technique 
(Vectastain ABC kit, Vector Laboratories Inc., Burlingame, USA).  To label differently 
phosphorylated tau proteins, five monoclonal antisera, AT8 (diluted 1:1000), AT180 
(diluted 1:2000) and HT7, all purchased from Innogenetics, USA, and Tau 2 (1:400) and 
Tau 5 (1mg/ml), both purchased from PharMingen International, San Diego, CA, were 
used.  Amyloid deposits were labeled with a monoclonal anti-BAP antiserum (clone 4G8, 
diluted 1:2000; Sennetek, USA).  All sections were heated in a hydrated microwave (750 
watts, 60 minutes) following by treatment with a 0.3% hydrogen peroxidase solution for 
10 minutes.  The sections for BAP labeling were pretreated with a 90% formic acid 
solution for 5 minutes.  The TUNEL technique employed an “ApopTag” in situ 
apoptosis detection kit (Oncor, Gaithersburg, MD) to label DNA termini in the sections.  
Sections for TUNEL labeling were first treated with proteinase K (20µg/ml for 2 min at 
room temperature), and the endogenous peroxidase activity was quenched with 0.3% 
H2O2 for 5min.  The working strength TdT enzyme mixture was pipetted onto 
slide-mounted tissue sections, coverslipped, and incubated for 1h at 37 degrees.  The 
sections were then incubated in a working strength stop/wash buffer for 10 min, 
incubated with anti-digoxigenin peroxidase conjugate and developed with a 
diaminobenzidine (DAB)-nickel ammonium solution to which were added a 0.6% nickel 
ammonium solution, 0.005M imidazole and 0.0002% H2O2 in 0.05M TRIS-HCL buffer, 
pH 7.6).  Double immunolabeling of  the above-mentioned anti-tau antisera and 
TUNEL-positive nuclei was performed to confirm the co-localization of  the apoptotic 
nuclei and tau-positive neurons in several sections.  Briefly, the TUNEL-stained sections 
were processed with tau labeling and developed with DAB solution.  The materials 
stained during TUNEL turned dark blue and those during the tau labeling brown.  Brain 
sections were also stained with the Gallyas silver impregnation technique to assess 
neuropathological staging [37]. 
 
Quantitative method 
Four hemispheric coronal sections were prepared to localize the counting areas for 
TUNEL and Gallyas staining and tau labeling.  The first section was prepared for 
examination of  the lateral prefrontal cortex and was defined as the section through the 
temporal pole, and the second section as the section through the lateral geniculate body, 
containing the temporal neocortex, entorhinal cortex and the sector 1-4 of  the cornu 
ammonis (CA).  The third section for examination of  the parietal cortex was defined as 
the section through the precuneus, and the fourth section for examination of  the occipital 
cortex as the section through Gennari’s line.   
For quantification of  the tau-labeled, TUNEL- and Gallyas-stained cells, the cells 
were viewed with a Nikon Eclipse E600, and the images captured with a Polaroid 
Microscopic Camera (Polaroid Corporation, Cambridge, MA) and displayed with 
Macintosh Adobe Photoshop 5.0.  In each visual field (vf) (X20 objective and X10 
eyepiece, 1vf=0.00168 mm2) printed out in color, the stained cells were counted 
independently by two of  the authors (KK and MH).  The density of  tau-labeled neurons, 
Gallyas-stained NFT and TUNEL-positive neuronal nuclei was determined by averaging 
the densities in five non-overlapping visual fields.  Evaluation of  the tissue changes and 
fibrillary gliosis with, respectively, H-E and with Holzer stained preparations has been 
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described elsewhere [25].  Statistical analysis employed analysis of  variance (ANOVA), 
Student’s t-test and Pearson’s correlation analysis with Stat View 5.0 and SPSS for 
Microsoft Windows.  Statistical significance was set at p<0.05. 
 
Results 
With tau and TUNEL double labeling, TUNEL-stained nuclei in the AD brains 
co-localized more frequently with AT180- and AT8-positive neurons than with neurons 
positive for the other anti-tau antisera, and many glial nuclei were also stained with the 
TUNEL technique (Figure 1).  However, apoptotic bodies were rarely observed, and 
condensation of  nuclear chromatin only occasionally, while no membrane bleb formation 
was identified.  TUNEL and tau double labeling resulted in a reduced intensity of  tau 
immunoreactivity compared with single labeling with either.  AT180 and AT8 labeling 
appeared to be most sensitive for visualization of  neuritic threads.  Tau2 and Tau5 
frequently labeled not homogeneous but coiled- or tangle-shaped NFT.  BAP labeling 
with 4G8 antiserum revealed abundant deposits of  BAP and tau labeling and the Gallyas 
technique a sufficient number of  senile plaques to fulfill the pathological criteria for AD 
[35-36].  Technical difficulties with double staining with the TUNEL and Gallyas 
techniques made it impossible to determine any co-localization of  Gallyas-stained NFT 
and TUNEL-stained nuclei.  Control brains contained hardly any TUNEL-stained cells 
and tau immunolabeling showed a limited number of  positive neurons in the entorhinal 
cortex, CA and temporal cortex.  4G8 labeling showed only diffuse, non-neuritic plaques 
in the cerebral cortex, which did not fulfill the AD diagnostic pathological criteria [35-36].  
The absence of  TUNEL-stained neurons in control brains made it impossible to perform 
a comparative analysis of  correlation between TUNEL and tau labeling in AD brains and 
that in the control brains.  The anti-tau antisera diffusely labeled neuronal cell bodies and 
visualized neuritic threads and dystrophic neurites around the neuritic plaques.  With the 
Gallyas technique, NFT were accentuated in the entorhinal cortex, CA and 
occipito-parietal cortex, a phenomenon compatible with stage-related NFT involvement 
in AD [25, 37]. 
In the AD brains, there was no statistical difference in the error variance density 
of  neurons positive for five anti-tau antisera (AT180: p=0.009, AT8: p=0.022, HT7: 
p=0.003, Tau2: p=0.0001, Tau5: p=0.001), Gallyas-stained NFT (p=0.0001) and 
TUNEL-positive neuronal nuclei (p=0.0001) among the AD cases examined. 
The density of  TUNEL-stained neuronal nuclei, expressed as mean value (mean) 
± standard deviation (S.D), in the seven cerebral regions showed region-specific 
distribution (Figure 2), and the results of  statistical analysis with two-tailed Student’s t-test 
are shown in Table 1 TUNEL.  The frontal cortex showed a density of  1.1 ± 1.4 (mean 
± S.D), which was significantly lower than the density of  the other cerebral regions (CA: 
t=8.646, p<0.0001; entorhinal cortex: t=5.988, p<0.0001; cingulate: t=8.821, p<0.0001; 
temporal: t=4.734, p<0.0001; parietal: t=6.891, p<0.0001; occipital: t=7.138, p<0.0001).  
The density of  TUNEL-stained neurons was 11.5 ± 6.4 in the entorhinal cortex, 9.0 ± 4.1 
in the parietal cortex, 8.6 ± 3.3 in the CA and 8.6 ± 4.7 in the occipital cortex.  The two 
highest t values were detected in following pairs: t=8.821 between the frontal cortex and 
the cingulate cortex, and t=8.646 between the frontal cortex and the CA.  For these four 
regions, GML multivariate analysis demonstrated that TUNEL-stained neuron density of  
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the occipital cortex was significantly higher than that of  the CA (p=0.001), and that the 
CA had a higher density of  TUNEL-stained neurons than did the frontal (p=0.0001) or 
cingulate cortex (p=0.004).  No significant difference was found between the CA and 
entorhinal cortex.  The entorhinal cortex had a significantly high density of  
Gallyas-stained NFT and AT8-positive neurons. 
Regional differences in density of  neurons positive for the five anti-tau antisera 
and Gallyas-stained NFT were analyzed with the unpaired t-test and many significant 
differences in density of  labeled neurons among the cerebral regions.  The rough 
estimate of  the distribution pattern, represented by the of  shaded box for insignificant t 
values and the open boxes for significant t values in Table 1, indicates that the pattern for 
TUNEL-stained neuron density was quite different from that for neurons labeled with 
other methods, that is, the former featured an absence of  significant differences in the 
density of  labeled neurons between the CA and entorhinal cortex.  Density distribution 
pattern of  neurons positive for AT8 (Table 1 AT8) and AT180 (Table 1 AT180) were very 
similar to each other, and it is likely that Tau2 (Table 1 Tau2) and Tau5 (Table 1 Tau5) 
roughly labeled Gallyas-stained NFT (Table 1 Gallyas).  Fewer significant pairs were 
observed for HT7 labeling than for the other labeling methods (Table 1 HT7). 
Pearson’s correlation analysis of  the average density in all regions of  total 
neurons positive for the five anti-tau antisera, TUNEL-stained neuronal nuclei and 
Gallyas-stained NFT showed that TUNEL-stained neuronal density correlated positively 
with that of  neurons positive for AT8 (r=0.210, p=0.011), Tau2 (r=0.175, p=0.037) and 
AT180 (r=0.175, p=0.037).  Correlation analysis of  the seven regions showed an inverse 
correlation between the density of  TUNEL-stained neurons and that of  AT8-positive 
(r=-0.702, p=0.0001) and Gallyas-stained NFT (r=-0.562, p=0.001) in the CA as well as 
that of  AT180-positive neurons (r=-0.430, p=0.018) in the temporal neocortex.  In 
contrast, TUNEL-stained neuronal density correlated positively with the density of  
AT8-positive neurons (r=0.556, p=0.039), HT7 (r=0.555, p=0.040) and Tau5 (r=0.579, 
p=0.005) in the frontal neocortex and Tau5 (r=0.818, p=0.004) in the occipital cortex.  
There was no statistical correlation in density between TUNEL-stained neurons and 
tau-positive or Gallyas-stained NFT in the cingulate gyrus, entorhinal cortex or parietal 
cortex.   
The ratio of  neurons labeled with each of  the anti-tau antisera to the 
TUNEL-labeled nuclei was 26.5% for AT180, 28.9%for AT8, 36.9% for HT7, 81.2% for 
Tau2, 40.7% for Tau5 and 22.8% for Gallyas technique, shown in Figure 3.  The ratios 
of  Tau2-labeled neurons to TUNEL-labeled neurons were markedly high, ranging from 
26% to 81%, in the CA, entorhinal cortex, temporal cortex, cingulate cortex and parietal 
cortex.   
 
Discussion 
Post-mortem delay in our AD cases, which ranged from 3.0 to 8.4 hours, was found to 
make only a minor contribution to an increase in apoptotic cells [25, 38].  Regional 
density of  tau-positive neurons, Gallyas-stained NFT and TUNEL-stained neuronal 
nuclei showed no statistically significant differences among the AD cases in our study.  
Therefore, inter-case differences in density of  NFT and TUNEL-stained neurons among 
AD cases can be neglected for the purpose of  this study.   
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The density of  TUNEL-stained neuronal nuclei was significantly low in the 
frontal cortex and high in the CA, entorhinal and parieto-occipital cortex.  This pattern 
roughly reflects the stage-related NFT involvement of  cerebral regions [37].  
Co-localization of  tau immunoreactivity and TUNEL-stained nuclei was not observed in 
the control brains irrespective of  the presence of  limited numbers of  tau-labeled neurons.  
The absence of  TUNEL-stained nuclei in tau-positive neurons in the control brains 
suggests that cell death in conjugation with the accumulation of  abnormally 
phosphorylated tau does not occur in non-demented individuals.   
Our study confirmed the presence of  TUNEL-labeled nuclei in tau-labeled 
neurons.  Because of  the reduced labeling sensitivity in TUNEL and tau double labeling, 
we were unable to directly count tau-positive neurons with TUNEL-stained nuclei.  
Although the precise ratio of  TUNEL-stained nuclei to tau-positive neurons must thus 
remain unknown, a certain amount of  tau-positive neurons can be regarded as the 
equivalent of  pretangle neurons.  More significantly, the density of  AT8-positive neurons 
showed a significantly inverse or direct correlation with that of  TUNEL-stained neurons 
in the frontal and CA regions.  Uchihara et al [28] identified sequential changes in NFT 
antigenicity from AT8 to Gallyas positivity, in which Gallyas-unstained and AT8-labeled 
NFT were identified and diffusely AT8-labeled neurons largely corresponded to pretangle 
neurons.  In this context, apoptosis defined as TUNEL positivity can occur in pretangle 
neurons, and regional differences in density of  both TUNEL-stained and tau-labeled 
neurons may constitute supportive evidence for the occurrence of  apoptosis at the 
pretangle neuron stage. 
Studies both proving and disproving the co-localization of  apoptosis and NFT 
have been published as neuropathological report and some of  them indicate a lack of  the 
typical apoptotic morphology in AD brains.  Su et al [1], using the AT8 and PHF1 
labeling and ISEL technique, failed to find a direct correlation between the 
phosphorylation site of  tau protein and DNA fragmentation in the CA of  AD.  In 
contrast, Sugaya et al [9] reported a tendency for more strongly tau-labeled neurons to 
exhibit DNA fragmentation more frequently.  And in a recent study [18], 
TUNEL-stained nuclei with normal morphology were more frequently associated with tau 
accumulation than were more severely damaged nuclei.  A study using double labeling of  
ISEL and MN423, an anti-tau antiserum that recognizes tau molecules terminating at 
Glu-391 [22], reported a high frequency of  co-localization of  ISEL-positive DNA 
fragmentation and MN423-positive neurons, 61-79% of  which showed DNA 
fragmentation.  The authors speculated that tau molecule truncation was an important 
trigger of  DNA fragmentation.  Biochemical studies [24-25] reported that abnormal 
phosphorylation begins mainly in the neurites in the early stage of  apoptosis, but that 
phosphorylated tau proteins are again dephosphorylated in the late stage.  AT8 was 
identified as a marker for early phosphorylation sites of  tau protein in AD and many 
AT8-positive neurons with TUNEL-unstained normal nuclei were observed.  Therefore, 
the presence of  such cells implies that the apoptotic process follows the initial 
phosphorylation but also that the apoptotic process may be reversible.  This issue will be 
more precisely clarified by use of  apoptosis-related proteins such as caspase-3 to localize 
apoptotic change because caspase-3 expression of  neurons was shown to be closely 
associated with apoptotic change [15, 20, 24]. 
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The frontal cortex and CA showed contrasting correlation for the density of  
TUNEL-stained nuclei and of  neurons positive for AT8.  The CA showed a higher 
density of  Gallyas-stained NFT and AT8-positive neurons than did the frontal cortex.  
Because the CA and entorhinal cortex are an initial target region for NFT [34], necrotic 
neuronal change can be assumed to be the most drastic compared with the other cerebral 
lesions.  The frontal cortex was affected lately by NFT and showed no correlation 
between the density of  Gallyas-stained NFT and TUNEL-stained neurons, while HT7 
expression showed more phosphorylation sites than that of  AT8.  This indicates that the 
scarcity of  argyrophilic NFT and its relative abundance in pretangle neurons result in the 
significantly direct correlation in the frontal cortex.  Bax and Bcl2 were shown to be 
increased in NFT-free neurons and decreased after NFT formation [21].  Although it 
should be confirmed whether pretangle neurons show an increase in these two proteins, 
discrepancy between apoptosis and NFT formation might be explained by modulation 
with these two proteins.  
 The density of  neurons positive for anti-tau antisera other than Tau2 generally 
indicated a predominant density of  TUNEL-stained nuclei.  This evidence suggests that 
abnormal phosphorylation of  tau protein precedes apoptotic nuclear change.  The high 
ratio of  Tau2-positive neurons to TUNEL-stained nuclei is considered to be due to 
neuronal loss caused by late stage NFT because Tau2 tended to label typical tangle-shaped 
NFT.  Amyloid fibril formation has been shown to be one factor associated with tau 
protein phosphorylation in AD [39], and early tau deposition is regulated by 
phosphorylated map kinase [16].  Apoptosis is essentially an intrinsic mechanism, so that 
factors (reviewed in [15]) merely accelerate or recover the process.  Raina et al [24] 
introduced “abortosis”; a novel term that indicates avoidance or recovery from 
caspase-induced programmed cell death in AD.  Early deposits of  abnormally 
phosphorylated tau was shown to be related with AD7c-neuronal thread protein, and its 
gene regulate expression of  this protein leading to neuronal cell death mediated by 
apoptosis [40-41].  These studies support our finding that apoptotic change follows 
phosphorylated tau protein deposits. 
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(a) Double labeling of  AT8 and TUNEL of  the frontal cortex (X400).  AT8-positive 
tangle-like structures (black arrows) are seen in the neuronal cytoplasm with 
TUNEL-stained nuclei.  A TUNEL-stained nucleus without AT8-positive structure is 
indicated with the white arrow.  (b) Double labeling of  AT180 and TUNEL of  the CA 
(X400).  Apoptotic bodies are indicated with the arrow.  AT180 frequently labeled 
neuropil threads, and the labeled neuron lacks fine structures of  the nucleus.  (c) Double 
labeling of  HT7 and TUNEL of  the cingulate cortex (X720).  HT7-positve and 
TUNEL-stained neurons (black arrows) show almost normal nuclei, and HT7 labels 
homogeneously the neuronal cell body.  
 
Figure 2 
The density of  labeled neurons (/0.00168mm2) of  the seven cerebral regions.  Error bars 
indicate standard deviation. 
 
Figure 3 
Percentile values of  ratio of  neurons labeled with TUNEL to those labeled with other 
methods. 




The results of  two-tailed Student’s t-test of  the density of  the labeled neurons by 
different labeling.  The open boxes for statistically significant t values and the shaded box 
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